Ethylenediamine

Summary

Ethylenediamine (CHEMBL816) is a phase-3 clinical-stage small-molecule GABA agonist; indicated across 2 conditions including drug-induced liver injury and metastatic prostate carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Chemistry: 60.1 Da · C2H8N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL816
Name	Ethylenediamine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3301
ChEBI	CHEBI:30347
Molecular formula	C2H8N2
Molecular weight	60.1
InChIKey	PIICEJLVQHRZGT-UHFFFAOYSA-N

SMILES: C(CN)N

IUPAC name: ethane-1,2-diamine

ChEBI definition: An alkane-α,ω-diamine in which the alkane is ethane.

Pharmacological roles (ChEBI): GABA agonist.

Also known as: Edamina, Edamine, Ethylene diamine, Ethylenediamine, PB-05721, PB05721, SID17389605, SID144204696, SID144208400, ETHYLENEDIAMINE

Patent coverage: 200,768 distinct patent families (532,379 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
drug-induced liver injury	3	MONDO:0005359	EFO:0004228
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).